PTC Therapeutics (PTCT) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

PTC Therapeutics Revenue Highlights


Latest Revenue (Y)

$937.82M

Latest Revenue (Q)

$135.42M

Main Segment (Y)

Collaboration Revenue

Main Geography (Y)

United States

PTC Therapeutics Revenue by Period


PTC Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$937.82M34.20%
2022-12-31$698.80M29.75%
2021-12-31$538.59M41.45%
2020-12-31$380.77M24.04%
2019-12-31$306.98M15.96%
2018-12-31$264.73M36.19%
2017-12-31$194.39M135.04%
2016-12-31$82.70M124.95%
2015-12-31$36.77M60.11%
2014-12-31$22.96M-26.70%
2013-12-31$31.33M8.85%
2012-12-31$28.78M-70.92%
2011-12-31$98.96M-

PTC Therapeutics generated $937.82M in revenue during NA 2023, up 34.20% compared to the previous quarter, and up 354.25% compared to the same period a year ago.

PTC Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30$135.42M-27.47%
2024-06-30$186.70M-11.14%
2024-03-31$210.12M-31.57%
2023-12-31$307.06M56.20%
2023-09-30$196.58M-8.06%
2023-06-30$213.81M-2.98%
2023-03-31$220.38M31.64%
2022-12-31$167.41M-22.90%
2022-09-30$217.13M31.17%
2022-06-30$165.53M11.29%
2022-03-31$148.74M-9.98%
2021-12-31$165.23M19.09%
2021-09-30$138.74M18.91%
2021-06-30$116.68M-1.07%
2021-03-31$117.94M-0.78%
2020-12-31$118.86M0.39%
2020-09-30$118.40M57.37%
2020-06-30$75.24M10.23%
2020-03-31$68.26M-29.24%
2019-12-31$96.46M35.07%
2019-09-30$71.42M-16.49%
2019-06-30$85.52M59.61%
2019-03-31$53.58M-37.94%
2018-12-31$86.34M61.11%
2018-09-30$53.59M-22.04%
2018-06-30$68.74M22.62%
2018-03-31$56.06M-28.15%
2017-12-31$78.03M86.44%
2017-09-30$41.85M-12.74%
2017-06-30$47.96M80.67%
2017-03-31$26.55M5.38%
2016-12-31$25.19M9.59%
2016-09-30$22.99M47.04%
2016-06-30$15.63M-17.26%
2016-03-31$18.89M24.17%
2015-12-31$15.22M55.69%
2015-09-30$9.77M53.49%
2015-06-30$6.37M17.77%
2015-03-31$5.41M-53.40%
2014-12-31$11.60M1355.71%
2014-09-30$797.00K-43.79%
2014-06-30$1.42M-84.50%
2014-03-31$9.15M132.70%
2013-12-31$3.93M-74.57%
2013-09-30$15.46M163.39%
2013-06-30$5.87M-3.37%
2013-03-31$6.07M2.60%
2012-12-31$5.92M-2.06%
2012-09-30$6.04M-0.36%
2012-06-30$6.06M-43.60%
2012-03-31$10.75M-

PTC Therapeutics generated $135.42M in revenue during Q3 2024, up -27.47% compared to the previous quarter, and up 63.34% compared to the same period a year ago.

PTC Therapeutics Revenue Breakdown


PTC Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 19Dec 18
Collaboration Revenue$100.03M--
Manufacturing$7.69M--
Product-$291.31M-
Grant And Collaboration-$15.67M-
Emflaza--$92.00M
Translarna--$171.00M
Early Stage Collaborations--$252.00M
Licensing And Collaboration Agreement--$200.00K
Grant---

PTC Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (92.86%), and Manufacturing (7.14%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Jun 23Mar 23Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
Royalty$61.37M$4.09M$696.00K----------------
Manufacturing$800.00K$1.36M$3.34M$2.36M$1.99M--------------
Product$135.42M$103.11M$91.28M$107.26M$82.71M$75.24M$68.20M$81.41M$71.37M$85.48M---------
Net product revenue-$177.60M-----------------
Grant And Collaboration-------$7.52M$35.00M-$63.00K$15.05M$47.00K$46.00K-----
Early Stage Collaborations--------------$252.00M----
Licensing And Collaboration Agreement--------------$100.00K$87.50M$100.00K$100.00K-
Discovery Agreements-------------------

PTC Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (68.54%), Royalty (31.06%), and Manufacturing (0.40%).

PTC Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
United States$531.66M$218.30M$187.30M--
Non-US$406.16M$288.60M$236.00M$190.30M-
Non Us---$194.40M-
U---$139.00M-
UNITED STATES----$116.68M

PTC Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: United States (56.69%), and Non-US (43.31%).

Quarterly Revenue by Country

CountryDec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21
United States$411.36M$65.70M$54.60M$58.20M$54.80M$56.80M$48.60M$47.50M-
Non-US$194.56M$96.50M$115.10M$55.70M$76.60M$77.00M$79.20M$69.70M-
Non Us--------$67.20M
U--------$47.10M

PTC Therapeutics's latest quarterly revenue breakdown by geography, as of Dec 23: United States (67.89%), and Non-US (32.11%).

PTC Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
SRPTSarepta Therapeutics$1.24B$362.93M
PTCTPTC Therapeutics$937.82M$135.42M
BPMCBlueprint Medicines$249.38M$128.18M
KRYSKrystal Biotech$50.70M$83.84M
IOVAIovance Biotherapeutics$1.19M$58.55M
VKTXViking Therapeutics--
MDGLMadrigal Pharmaceuticals-$62.17M
HEPAHepion Pharmaceuticals--

PTCT Revenue FAQ


What is PTC Therapeutics’s yearly revenue?

PTC Therapeutics's yearly revenue for 2023 was $937.82M, representing an increase of 34.20% compared to 2022. The company's yearly revenue for 2022 was $698.8M, representing an increase of 29.75% compared to 2021. PTCT's yearly revenue for 2021 was $538.59M, representing an increase of 41.45% compared to 2020.

What is PTC Therapeutics’s quarterly revenue?

PTC Therapeutics's quarterly revenue for Q3 2024 was $135.42M, a -27.47% decrease from the previous quarter (Q2 2024), and a -31.11% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $186.7M, a -11.14% decrease from the previous quarter (Q1 2024), and a -12.68% decrease year-over-year (Q2 2023). PTCT's quarterly revenue for Q1 2024 was $210.12M, a -31.57% decrease from the previous quarter (Q4 2023), and a -4.66% decrease year-over-year (Q1 2023).

What is PTC Therapeutics’s revenue growth rate?

PTC Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 74.12%, and for the last 5 years (2019-2023) was 205.50%.

What are PTC Therapeutics’s revenue streams?

PTC Therapeutics's revenue streams in c 23 are Collaboration Revenue, and Manufacturing. Collaboration Revenue generated $100.03M in revenue, accounting 92.86% of the company's total revenue Manufacturing generated $7.69M in revenue, accounting 7.14% of the company's total revenue

What is PTC Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of PTC Therapeutics was Collaboration Revenue. This segment made a revenue of $100.03M, representing 92.86% of the company's total revenue.